Kala Pharmaceuticals Inc
NASDAQ:KALA

Watchlist Manager
Kala Pharmaceuticals Inc Logo
Kala Pharmaceuticals Inc
NASDAQ:KALA
Watchlist
Price: 0.59 USD -2.09% Market Closed
Market Cap: $12.9m

Operating Margin

0%
Current
No historical data
Comparison unavailable

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
0%
=
$0
/
$0

Peer Comparison

Country Company Market Cap Operating
Margin
US
Kala Pharmaceuticals Inc
NASDAQ:KALA
12.9m USD
Loading...
US
Eli Lilly and Co
NYSE:LLY
1T USD
Loading...
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP
Loading...
US
Johnson & Johnson
NYSE:JNJ
525.7B USD
Loading...
CH
Roche Holding AG
SIX:ROG
277.8B CHF
Loading...
UK
AstraZeneca PLC
LSE:AZN
212.4B GBP
Loading...
CH
Novartis AG
SIX:NOVN
221.9B CHF
Loading...
US
Merck & Co Inc
NYSE:MRK
271.6B USD
Loading...
DK
Novo Nordisk A/S
CSE:NOVO B
1.8T DKK
Loading...
IE
Endo International PLC
LSE:0Y5F
218B USD
Loading...
US
Pfizer Inc
NYSE:PFE
148.4B USD
Loading...

Market Distribution

Not Available
No Country distribution data available for this multiple

Kala Pharmaceuticals Inc
Glance View

Market Cap
12.9m USD
Industry
Pharmaceuticals

Kala Pharmaceuticals, Inc. is a biopharmaceutical company. The company is headquartered in Arlington, Massachusetts and currently employs 192 full-time employees. The company went IPO on 2017-07-20. The firm's product candidate includes EYSUVIS (loteprednol etabonate ophthalmic suspension) 0.25% and INVELTYS (loteprednol etabonate ophthalmic suspension) 1%. Its EYSUVIS product is a short-term (up to two weeks) treatment of the signs and symptoms of dry eye disease. INVELTYS product is a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. The firm's AMPPLIFY technology uses selectively-sized nanoparticles that each have a coating. The firm also has a pipeline of development programs, including a clinical-stage secretome product candidate, KPI-012, initially targeting persistent corneal epithelial defects (PCED) and multiple new chemical entity (NCE) preclinical development programs targeted to address unmet medical needs.

KALA Intrinsic Value
0.67 USD
Undervaluation 12%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Back to Top